Table 1 Characteristics of NAFLD pediatric population

Age (years)

12.0 (10.0–14)

11.0 (6.8–15.3)

0.606

Gender (M/F)

141/20

54/8

0.923

BMI z-score

-0.05 (-0.91–0.47)

0.18 (-0.42–0.82)

0.04

Platelet (10^9/L)

284 (244–334)

248 (208–286)

 < 0.001

Albumin (g/L)

45.0 (43.0–47.0)

42.5 (40.0–47.0)

0.018

Globulin

27 (24–29)

24 (27–29)

0.321

Prealbumin (mg/L)

232 (207–263)

151 (137–185)

 < 0.001

ALT (U/L)

143 (85–237)

87.0 (51–124)

 < 0.001

AST (U/L)

79 (49–128)

68 (46–87)

0.120

GGT(U/L)

60 (42–91)

25 (21–45)

 < 0.001

TBA (umol/L)

6 (3–8)

7 (5–13)

0.002

Creatinine (umol/L)

55 (47–63)

49 (44–61)

0.050

Cholinesterase (U/L)

9822 (8579–10,609)

7359 (6710–8925)

 < 0.001

Urid acid (umol/L)

382 (310–443)

291 (271–369)

 < 0.001

Fibrinogen (g/L)

3.10 (2.57–3.53)

2.74 (2.22–3.28)

0.020

PT (s)

10.9 (10.4–11.4)

11.4 (10.9–12.1)

 < 0.001

TC (mmol/L)

4.36 (3.85–4.97)

3.7 (3.4–4.3)

 < 0.001

TG (mmol/L)

1.47 (1.15–1.97)

0.90 (0.78–1.28)

 < 0.001

HDL-C (mmol/L)

1.10 (0.99–1.31)

1.20 (1.03–1.29)

0.189

LDL-C (mmol/L)

2.96 (2.55–3.45)

2.31 (2.06–2.84)

 < 0.001

ApoA1 (mmol/L)

1.22 (1.12–1.37)

1.28 (1.15–1.38)

0.191

ApoB (mmol/L)

0.81 (0.67–0.97)

0.61 (0.53–0.72)

 < 0.001

Lp (a) (mmol/L)

46 (29–80)

62 (29–76)

0.291

Metabolic syndrome (n, %)

27 (18.9%)

1 (1.6%)

0.001

Hepatic steatosis

 < 0.001

 Mild (n, %)

12 (7.5%)

46 (73.2%)

 Moderate (n, %)

40 (24.8%)

11 (17.7%)

 Severe (n, %)

109 (67.7%)

5 (8.1%)

Stage of Fibrosis

0.928

 S0-1 (n, %)

79 (49.1%)

30 (48.4%)

 S2-4 (n, %)

82 (50.9%)

32 (51.6%)

Grade of Necro

0.034

 A0-1 (n, %)

98 (60.9%)

28 (45.2%)

 A2-3 (n, %)

63 (39.1%)

34 (54.8%)

 HBsAg(COI)

-

2162 (1108–5256)

 HBeAg(COI)

-

410 (6.4–1026)

 HBV DNA (copy/ml)

-

8.79 (0.84–23.53) × 10⁷

HBV Genotype

 B

-

12

 C

-

34